Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Oct 27, 2013; 5(10): 596-600
Published online Oct 27, 2013. doi: 10.4254/wjh.v5.i10.596
Published online Oct 27, 2013. doi: 10.4254/wjh.v5.i10.596
Case | Sex | Age | Stage | CP | Previous treatment | Duration (mo) | Response | Cause of death |
1 | F | 64 | IVA | A | 5FU + IFN, Sorafenib | 3 | PD | HCC progression |
2 | F | 85 | IVA | C | None | 3 | SD | HCC progression |
3 | M | 63 | IVA | C | None | 6.5 | SD-PD | HCC progression |
4 | M | 57 | IVA | A | TACE | 3 | PD | HCC progression |
5 | F | 73 | IVA | C | None | 6 | PD | Survived |
This case | F | 60 | IVB | A | Surgery, RFA, TAI | 17 | PR | Survived |
-
Citation: Hoshino T, Takagi H, Naganuma A, Koitabashi E, Uehara S, Sakamoto N, Kudo T, Sato K, Kakizaki S. Advanced hepatocellular carcinoma responds to MK615, a compound extract from the Japanese apricot “
Prunus mume ”. World J Hepatol 2013; 5(10): 596-600 - URL: https://www.wjgnet.com/1948-5182/full/v5/i10/596.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i10.596